Center for Scientific Review; Notice of Closed Meetings, 39201 [2020-14022]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 126 / Tuesday, June 30, 2020 / Notices
Dated: June 25, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–14058 Filed 6–29–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Conflicts in
Nephrology.
Date: July 27, 2020.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jonathan K. Ivins, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2190,
MSC 7850, Bethesda, MD 20892, (301) 594–
1245, ivinsj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cancer Biology.
Date: July 27, 2020.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Amy L. Rubinstein, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5152,
MSC 7844, Bethesda, MD 20892, 301–408–
9754, rubinsteinal@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflicts: Cardiovascular Sciences.
Date: July 28–29, 2020.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
18:18 Jun 29, 2020
Jkt 250001
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Bradley Nuss, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4142,
MSC 7814, Bethesda, MD 20892, 301–451–
8754, nussb@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
conflicts: Topics in Hepatology,
Pharmacology, and Environmental
Toxicology.
Date: July 28, 2020.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Aiping Zhao, MD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2188,
MSC 7818, Bethesda, MD 20892–7818, (301)
435–0682, zhaoa2@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 24, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–14022 Filed 6–29–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Request for Letters of Interest (LOI) for
NCI–MATCH Laboratories
National Institutes of Health,
Health and Human Services (HHS).
ACTION: Notice, extension.
AGENCY:
The National Cancer Institute
(NCI) through its National Clinical
Trials Network (NCTN) is developing a
successor precision medicine trial to
‘NCI-Molecular Analysis for Therapy
Choice (NCI–MATCH)’ entitled ‘NCIComboMATCH’. The principal of this
intiative is to overcome drug resistance
to single-agent therapy by developing
genomically-directed targeted agent
combinations. All combinations must be
supported by robust, preclinical in vivo
evidence. Due to the coronavirus
pandemic the NCI is providing an
extension of the previously published
notice in the Federal Register on March
11, 2020 to allow candidate more time
to submit LOIs. NCI-ComboMATCH trial
leadership invites applications for
SUMMARY:
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
39201
Clinical Laboratory Improvements
Program (CLIA) certified/accredited
laboratories that test tumor specimens
from patients utilizing Next-Generation
Sequencing (NGS) assays to participate
in the NCI-ComboMATCH trial. In order
to support this trial, the designated
laboratories participating in NCIComboMATCH will identify patients for
the specific variants needed for trial
eligibility. Laboratories will be required
to contact any of the NCTN sites that
have activated NCI-ComboMATCH if a
specimen sent from one of these sites
has a variant(s) that would potentially
make the patient eligible for one of the
treatment arms.
DATES: The due date for Letters of
Interest (LOIs), published on March 11,
2020 (85 FR 14208), has been extended
and should now be submitted to the
National Cancer Institute (NCI),
National Institutes of Health (NIH) on or
before 5:00 p.m. EST on September 30,
2020.
ADDRESSES: Submit LOIs by email to
NCICOMBOMATCHLabApps@nih.gov.
9609 Medical Center Drive, 3 West,
Room 526, MSC 9728, Rockville, MD
20892.
FOR FURTHER INFORMATION CONTACT:
Questions about this request for LOIs
should be directed to
NCICOMBOMATCHLabApps@nih.gov.
James V. Tricoli, 240–276–5725 or
tricolij@mail.nih.gov, can also provide
further information.
SUPPLEMENTARY INFORMATION: This
notice was previously published in the
Federal Register on March 11, 2020,
page 14208–14210 (85 FR 14208). The
purpose of this notice is to allow an
additional 90 days for submission of the
LOI. The due date for LOI submission
has been extended from the previous
date of June 30, 2020 to September 30,
2020 to allow more labs to submit. This
is necessary due to the impact of the
coronavirus pandemic. In accordance
with 42 U.S.C. 285, of the Public Health
Service Act, as amended. Similar to
NCI–MATCH, NCI-ComboMATCH is
conceived as a signal-seeking study. The
NCI-ComboMATCH team will
determine whether patients with tumor
mutations, amplifications or
translocations in the genetic pathway(s)
of interest are likely to derive clinical
benefit if treated with a combination of
precision medicine agents targeting
those specific pathway(s). This
recruitment is for labs that can
specifically screen 200 patients seen at
NCTN sites per month.
Patients with histologically
documented solid tumors, lymphomas
and multiple myeloma whose disease
has progressed following at least one
E:\FR\FM\30JNN1.SGM
30JNN1
]]>Agencies
[Federal Register Volume 85, Number 126 (Tuesday, June 30, 2020)]
[Notices]
[Page 39201]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-14022]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Conflicts in Nephrology.
Date: July 27, 2020.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jonathan K. Ivins, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2190, MSC 7850, Bethesda, MD
20892, (301) 594-1245, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Cancer Biology.
Date: July 27, 2020.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Amy L. Rubinstein, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5152, MSC 7844, Bethesda, MD
20892, 301-408-9754, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflicts: Cardiovascular Sciences.
Date: July 28-29, 2020.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Bradley Nuss, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4142, MSC 7814, Bethesda, MD 20892, 301-451-
8754, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member conflicts: Topics in Hepatology, Pharmacology, and
Environmental Toxicology.
Date: July 28, 2020.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Aiping Zhao, MD, Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 2188, MSC 7818, Bethesda, MD 20892-7818, (301)
435-0682, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: June 24, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-14022 Filed 6-29-20; 8:45 am]
BILLING CODE 4140-01-P
